Structure Therapeutics Inc. — Earnings Release 2026

Feb 26, 2026

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Field: Rule-Page

Field: /Rule-Page

FORM 8-K

Field: Rule-Page

Field: /Rule-Page

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 26, 2026

Field: Rule-Page

Field: /Rule-Page

Structure Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Field: Rule-Page

Field: /Rule-Page

| Cayman
Islands | 001-41608 | 98-1480821 |
| --- | --- | --- |
| (State
or other jurisdiction of incorporation) | (Commission File
Number) | (IRS Employer Identification
No.) |

| 601
Gateway Blvd. , Suite 900 South
San Francisco , California | 94080 |
| --- | --- |
| (Address
of principal executive offices) | (Zip
Code) |

(Registrant’s telephone number, including area code): ( 650 ) 457-1978

Not Applicable

(Former name or former address, if changed since last report)

Field: Rule-Page

Field: /Rule-Page

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title
of Each Class | Name Of Each Exchange Trading Symbol(s) | O n Which
Registered |
| --- | --- | --- |
| American
Depositary Shares (ADSs), each representing three ordinary shares, par value $0.0001 per ordinary share | GPCR | Nasdaq Global Market |
| Ordinary
shares, par value $0.0001 per share | True | Nasdaq Global Market |

• Not for trading, but only in connection with the registration of the American Depositary Shares

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

Item 2.02 Results of Operations and Financial Condition.

On February 26, 2026, Structure Therapeutics Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
No.	Description
99.1	Press
Release dated February 26, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Field: Page; Sequence: 2

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Raymond Stevens
Raymond Stevens, Ph.D.
Chief Executive Officer

Field: Page; Sequence: 3; Options: Last

Field: /Page

Field: Set; Name: xdx; ID: xdx_08B_extensions eJxFjU0KwjAQhU/QOwxZi6bxZ9GdFhWxihQRt9FOJdhmyiT+HclbGlvEYWAY3vveE6InlrQwFTIcZ3kGe6ybSnuEHEtktGcMjnS1TiDcHC/GedbWt+8PTCkwGJhxX6lTEFrr3TgsEpCTgRwO1AhknKgxTDci+uop2dIUaL3RFWhbwI6pYYNe86tL2OsnWapfbdUB2RmyCcR92clvUDJWsKW7fhBfHWRZKqJeO5FYMt2a4Jo/PdovCfMK61DnOvq/0Qf8gkp7